* Ensysce Biosciences Inc ENSC.OQ reported a quarterly
adjusted
loss of $1.37 per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of $-18.24. The mean expectation of three analysts
for the quarter was for a loss of 87 cents per share. Wall
Street expected results to range from -93 cents to -81 cents per
share.
* Revenue fell 64.1% to $515.03 thousand from a year ago;
analysts
expected $395.00 thousand.
* Ensysce Biosciences Inc's reported EPS for the quarter was
a
loss of $1.37.
* The company reported a quarterly loss of $3.5 million.
* Ensysce Biosciences Inc shares had fallen by 23.6% this
quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Ensysce
Biosciences Inc is $16.30
This summary was machine generated from LSEG data March 19 at
09:00 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -0.87 -1.37 Missed
Sep. 30 2023 -1.06 -0.87 Beat
Jun. 30 2023 -2.73 -0.98 Beat
Mar. 31 2023 -5.08 -2.08 Beat